Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT1621 in Treatment Naïve Pediatric/Adolescent TK2 Deficiency
NCT04581733Phase 3Withdrawn
- Sponsor
- Zogenix, Inc.
- Start
- Sep 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of MT1621 in thymidine kinase 2 deficiency (TK2D), sponsored by Zogenix, Inc.. Planned start Sep 2022; status: withdrawn.
02
Drugs
MT1621
03
Conditions
thymidine kinase 2 deficiency (TK2D)
Beyond the preview
Go deeper on NCT04581733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04581733.